FDA approves novel topical gel for adolescent acne

August 5, 2005

The Food and Drug Administration (FDA) last week approved a topical acne gel developed and manufactured by the Canadian drug company QLT Inc. for use for patients between 12 and 17 years old.

The Food and Drug Administration (FDA) last week approved a topical acne gel developed and manufactured by the Canadian drug company QLT Inc. for use for patients between 12 and 17 years old.

The Vancouver (British Columbia)-based company, says that its product, to be sold under the name Aczone, is the only topical acne treatment containing dapsone, a drug that, taken in pill form, is used to treat certain skin rashes and leprosy. A representative of QLT says potential patients will need to be screened for glucose-6-phosphate dehydrogenase (G6PD) deficiency before starting the therapy.

More from Contemporary Pediatrics Dateline.